🇪🇺 Fast delivery (3–5 working days) with GLS ✅ Card or bank transfer 📦 Free shipping from €50
ACE-031
ACE-031 1 mg – ActRIIB-Fc ligand trap for myostatin and activin
Peptology Ltd. · Recovery and anabolic peptides
ACE-031 1 mg (ActRIIB-Fc) – recombinant fusion protein of the extracellular domain of activin receptor type IIB and the Fc part of human IgG1 – a soluble "ligand trap" for the myostatin/activin pathway; research protein (the clinical DMD programme was discontinued). Purity 99%+, HPLC/MS report for every batch. Reconstitution: 1 mL BAC → 1 mg/mL.
📦 The product is in our EU warehouse – delivery within 3–5 working days.
40,00 € · Out of stock
For research use only / Not a medicine
| Purity | >99% |
|---|---|
| Method | HPLC + LC/MS |
| Laboratory | Analiza Białek |
| Batch | 0226 |
Last updated: 02/10/2026
What is ACE-031 (1 mg)?
ACE-031 is a recombinant ActRIIB-Fc fusion protein — a combination of the extracellular domain of the activin receptor type IIB (ActRIIB) with a fragment of human IgG1-Fc. It acts as a "ligand trap": it binds and neutralizes myostatin (GDF-8), activins and certain GDF/BMP ligands, thereby inhibiting the negative regulators of muscle growth. The result (in studies) is an increase in lean body mass and muscle volume.
A clarification is worthwhile: ACE-031 is not a classic small peptide, but a larger fusion protein with an Fc domain (which extends its half-life). In the Peptology catalog it is assigned to the category peptides for skin, sleep and libido, though functionally it belongs to the group of muscle- and bone-growth compounds — alongside the regenerative PEG-MGF.
Important safety note: The clinical program for ACE-031 in Duchenne muscular dystrophy (DMD) was terminated early due to reports of nosebleeds and telangiectasias (dilations of small blood vessels) and regulatory concerns. No phase III studies were published. The product offered by Peptology is exclusively a research-grade reagent — it is not a drug.
In the version offered by Peptology, ACE-031 is available in a 1 mg vial as a lyophilized compound with purity ≥ 99%, confirmed by independent laboratory analysis (CoA for every batch). The product is intended exclusively for scientific research and in vitro applications.
Variant: ACE-031 1 mg
This page concerns one dosage variant — ACE-031 1 mg. Each vial contains 1 mg of the lyophilized fusion protein. A typical working reconstitution is 1 mL → 1 mg/mL, which makes it easier to measure small volumes precisely in a research protocol.
VIAL · 1 MG
ACE-031 (ActRIIB-Fc)
1 mg of lyophilized fusion protein, purity ≥ 99% confirmed by CoA for every batch.
REFERENCE CONCENTRATION
1 mg/mL (at 1 mL)
Typical working reconstitution (preferably with Peptide Matrix Water™). Calculate in the calculator.
ACE-031 is offered in the 1 mg variant. Other compounds in the muscle growth/regeneration area are PEG-MGF (satellite cells) and IGF-1 LR3 (systemic IGF-1).
How ACE-031 works — the "ligand trap" mechanism
In the research literature, ACE-031 is described as a soluble decoy receptor inhibiting the myostatin/activin pathway. Below are the three most frequently studied elements.
MYOSTATIN TRAP
Binds and neutralizes myostatin (GDF-8), activins and GDF-11/BMP9/10 → ↓ signaling through ActRIIB.
MUSCLE / BONE GROWTH
Inhibition of negative regulators → increase in lean body mass and signals in bone biomarkers.
Fc FUSION
The Fc domain extends the circulating half-life and ensures systemic action.
Why myostatin blockade matters
Myostatin (GDF-8) is a natural "brake" on muscle growth — it limits muscle mass. By blocking it (and related ligands) via the ActRIIB-Fc decoy receptor, ACE-031 is studied as a tool for increasing muscle mass and strength and for modeling bone metabolism. This is a different mechanism from PEG-MGF (satellite cell activation) or IGF-1 LR3 (IGF-1 signaling).
It should be remembered, however, that the ActRIIB pathway also includes vascular ligands (BMP9/10) — which is associated with the adverse effects observed in the DMD studies (nosebleeds, telangiectasias). This data comes from clinical trials and does not constitute a claim about the effect of the research-grade product offered by Peptology.
Pharmacokinetics and pharmacodynamics (research framework)
ACE-031 is an ActRIIB-Fc fusion protein with extended systemic action. The most important research characteristics:
- Structure: the extracellular domain of ActRIIB fused to human IgG1-Fc (a fusion protein, not a small peptide)
- Targets: myostatin (GDF-8), activins, GDF-11, BMP9/10 — neutralization of ActRIIB ligands
- Half-life: extended thanks to the Fc domain (systemic action)
- Effects in studies: increase in lean mass and muscle volume after a single dose (phase I)
- Status: no phase III; the DMD program terminated for safety reasons
- Route of administration in protocols: subcutaneous, per the research protocol
Comparison: ACE-031 vs PEG-MGF vs 5-Amino-1MQ
Within the same category, it is worth comparing ACE-031 with two other compounds affecting muscle and body composition — the regenerative PEG-MGF and the metabolic 5-Amino-1MQ. Each acts by a completely different route.
| ACE-031 (this page) | PEG-MGF | 5-Amino-1MQ | |
|---|---|---|---|
| Compound type | ActRIIB-Fc fusion protein | IGF-1 isoform (pegylated) | Small-molecule NNMT inhibitor |
| Main mechanism | Myostatin/activin blockade | Satellite cell activation | NNMT inhibition (metabolism) |
| Main research area | Muscle mass growth, bone metabolism | Early muscle regeneration | Fat metabolism |
| Dose (this version) | 1 mg | 2 mg | 50 mg |
| Status / caution | DMD program terminated (safety) | No phase II/III RCT | Early research area |
ACE-031 increases muscle mass by blocking myostatin, PEG-MGF supports regeneration (satellite cells), and 5-Amino-1MQ concerns fat metabolism. It is worth emphasizing ACE-031's distinct safety profile (terminated DMD program). The comparison is indicative in nature and does not constitute a recommendation for use.
Research data on ACE-031
ACE-031 was studied clinically (phase I–II) before the program was suspended. Below are the most important observations — with a strong safety caveat.
Increase in muscle mass (phase I)
In phase I studies in healthy postmenopausal female volunteers (placebo-controlled), single doses of ACE-031 induced a rapid, dose-dependent increase in lean body mass and muscle volume, with signals in bone and fat biomarkers, with good tolerability after a single administration.
The DMD study and its termination
In a phase II study in boys with Duchenne muscular dystrophy, a trend toward preserved function and increased lean mass/BMD was observed, but the study was terminated after cycle 2 due to reports of nosebleeds and telangiectasias and as a result of regulatory discussions (FDA / Health Canada).
Current status
No phase III studies were published, and development work on ACE-031 was halted. It remains an object of scientific interest, mainly for research purposes on the myostatin pathway. This is not a confirmed therapeutic application.
Note: The information is presented for scientific and informational purposes and is based on the literature on ActRIIB-Fc / ACE-031. It does not constitute medical advice, a recommendation for use or a claim about the effect of the research-grade product offered by Peptology.
ACE-031 profile at a glance
- ActRIIB-Fc fusion protein — a "ligand trap" for myostatin/activin (not a small peptide)
- Blockade of the negative regulators of muscle growth → increase in lean mass (phase I)
- Effect on bone biomarkers — studied in the context of bone metabolism
- The Fc domain extends the half-life and systemic action
- Important safety note: the DMD program was terminated (nosebleeds/telangiectasias), no phase III
- Every batch with a CoA and purity ≥ 99%
All information provided refers to the research literature on ACE-031 and should not be interpreted as a promise of effect, an instruction for use or a claim about the effect of the research-grade product offered by Peptology.
Research dosing protocols
Important: The information below describes schedules used in research on ACE-031. It is provided for scientific and informational purposes and does not constitute a recommendation for individual use, medical advice or administration instructions. The research-grade ACE-031 offered by Peptology is not a registered drug, and its clinical program was terminated for safety reasons.
In studies, ACE-031 was administered subcutaneously after reconstitution of the lyophilizate:
- Working reconstitution: 1 mL → 1 mg/mL; calculate precise volumes in the peptide calculator
- In clinical trials a dose range was used (e.g. 0.02–3 mg/kg SC) — exclusively under supervised conditions
- Thanks to the Fc domain the action is long, so schedules were spread over time
- Due to the observed vascular effects (nosebleeds/telangiectasias), the safety profile requires particular caution
In a comparative context, ACE-031 is sometimes paired with other muscle-axis compounds, such as PEG-MGF or IGF-1 LR3. These schedules come from the research literature and do not constitute a recommendation for self-administration.
Side effects and safety
The safety profile of ACE-031 is a significant element of its research history — the clinical program in DMD was terminated. Below are the key observations from research on the molecule.
After a single dose
- Well tolerated in healthy female volunteers
- Mild local reactions
With repeated administration (DMD)
- Nosebleeds
- Telangiectasias (dilations of small blood vessels)
Key points
- Clinical program terminated
- No phase III data
- The vascular profile requires caution
While single doses were well tolerated in healthy volunteers, repeated administration in the DMD study was associated with vascular effects (nosebleeds, telangiectasias), which led to termination of the program. This underscores that ACE-031 has a significant safety profile to consider. This information is scientific in nature and does not constitute an instruction for use.
Storage and reconstitution
ACE-031 is supplied as a lyophilized (freeze-dried) powder in a vial. In lyophilized form it is stable at room temperature, protected from light and moisture — refrigeration before reconstitution is not mandatory. As a fusion protein it is sensitive to mechanical stress — reconstitute especially gently. After reconstitution, stability depends on the solvent used, with Peptide Matrix Water™ significantly extending the solution's lifespan.
- Before reconstitution: room temperature, in the original packaging, protected from light and moisture. A refrigerator is not mandatory.
- After reconstitution with Peptide Matrix Water™: stability in the refrigerator +2 °C to +8 °C for up to 60 days under appropriate laboratory conditions — the stabilizing formula extends the compound's lifespan relative to standard solvents.
- After reconstitution with bacteriostatic or sterile water: stability in the refrigerator +2 °C to +8 °C for up to 28 days under appropriate conditions. Do not refreeze the reconstituted solution.
- Reconstitution: in a laboratory setting, Peptide Matrix Water™, bacteriostatic water or sterile water for injection is usually used, depending on the protocol.
- Volume: maximum 3 mL of solvent (capacity of a standard vial). For a precise calculation of volume and units, use the peptide calculator.
- Homogenization: add the solvent slowly down the vial wall, without vigorous shaking, then wait 10–15 min. Swirl gently, do not shake.
Laboratory tip: With your order, you can add Peptide Matrix Water™ to the cart — a stabilizing solution designed for working with reconstituted research peptides and proteins. More in the article Bacteriostatic water vs acetic acid vs matrix water.
Frequently asked questions about ACE-031
What is the purpose of ACE-031?
ACE-031 is an ActRIIB-Fc that binds myostatin, activins and related ligands (including GDF-11, BMP9/10), reducing signaling through the ActRIIB receptor. The effect in studies is an increase in muscle mass. The results concern the molecule, not the research-grade product.
Why was the DMD work halted?
Due to reports of nosebleeds and telangiectasias and regulatory discussions, the program was terminated after cycle 2. This is a key element of the ACE-031 safety profile.
How does ACE-031 differ from PEG-MGF?
ACE-031 increases muscle mass by blocking myostatin (removing the "brake"), while PEG-MGF supports regeneration through satellite cell activation. These are two different mechanisms of the muscle axis.
How is ACE-031 stored and reconstituted?
The lyophilized vial is stored at room temperature, protected from light and moisture. After reconstitution, stability depends on the solvent: with Peptide Matrix Water™ — up to 60 days in the refrigerator +2 °C to +8 °C; with bacteriostatic or sterile water — up to 28 days. Avoid refreezing.
Where to buy ACE-031 for research?
Peptology offers ACE-031 (1 mg) as a research compound with confirmed purity ≥ 99% and independent laboratory analysis for every batch. Fast shipping, discreet packaging and certificates of purity with the product. For scientific background, also see the article Peptides — what they are, how they work, main categories and safety profile.
Related products in the Peptology catalog
Researchers working with ACE-031 often also consider other compounds of the muscle axis and body composition control. Each of the products below has a certificate of purity (CoA):
PEG-MGF
Muscle regeneration — satellite cells
IGF-1 LR3
Systemic IGF-1 action
5-Amino-1MQ
NNMT inhibitor — fat metabolism
GHRP-2
GH secretagogue — growth hormone axis
HGH Frag 176-191
Lipolytic hGH fragment
Peptide Matrix Water™
Stabilizing solution for reconstitution
See the full catalog: Peptides for skin, sleep and libido · Recovery and anabolic peptides · Peptides for energy and regeneration · All peptides · Blog on peptide research
Research warning: ACE-031 (ActRIIB-Fc) is offered exclusively for scientific research and in vitro purposes. It is not a medicinal product, is not approved for use in humans or animals, and does not replace medical advice. The clinical program for ACE-031 was terminated for safety reasons (nosebleeds/telangiectasias), and phase III studies were not published. All information comes from the research literature and is provided for scientific and informational purposes; it does not constitute a claim about the effect of the research-grade product offered by Peptology.
Laboratory reconstitution
Laboratory protocol — reconstitution, research protocols, storage
Standardized protocol applicable to all research peptides in the Peptology catalogue. To calculate the solution concentration (mg/mL) for each vial, use the peptide reconstitution calculator.
60-second protocol
1. SOLVENT
2. RECONSTITUTION
Add the solvent down the side of the vial, without shaking, wait 10–15 min.
3. CALCULATION
Calculator → concentration mg/mL
4. STORAGE
+2 °C to +8 °C, up to 60 days with Peptide Matrix Water
Quick reference
| Parameter | Value |
|---|---|
| Form | Lyophilized powder |
| Solvent | Peptide Matrix Water |
| Reconstitution volume | 1–3 mL — maximum 3 mL (capacity of the standard vial) |
| Storage before reconstitution | Room temperature, protected from direct light (refrigeration not required) |
| After reconstitution | Up to 60 days at +2 °C to +8 °C with Peptide Matrix Water |
What you need
Precision pipette
Calibrated, 100–1000 µL — for accurately measuring the volume of solvent added to the vial.
70% alcohol swabs
Two swabs — to disinfect the peptide vial and the solvent vial.
Stabilized solvent for lyophilized peptides. Why this one.
Five rules for reconstitution
| ✅ Correct | ❌ Mistake |
|---|---|
| Disinfect the vial caps and the work surface with 70% alcohol; wear gloves | Working without disinfection |
| Add the solvent slowly along the vial wall | Direct jet onto the powder — foaming and denaturation |
| Gentle rolling between the palms | Shaking — foam, which denatures peptides |
| 10–15 minutes waiting at room temperature | Mechanical mixing or heating |
| Visual check: clear, particle-free | Working with a cloudy or discolored solution |
Calculating concentration
⚠️ Maximum 3 mL solvent. The standard vial does not accommodate larger volumes — do not exceed during reconstitution.
- Concentration (mg/mL) = mg in the vial ÷ mL of solvent
- Volume per sample (mL) = amount per sample (mg) ÷ concentration (mg/mL)
- 1 mg/mL = 1 µg/µL · 1 mL = 1000 µL
Reconstitution per vial — solvent: Peptide Matrix Water. Concentration after adding the solvent (1 mg/mL = 1 µg/µL):
| Vial | + 1 mL | + 2 mL | + 3 mL |
|---|---|---|---|
| 1 mg | 1 mg/mL | 0.5 mg/mL | 0.33 mg/mL |
👉 For any vial and solvent volume — use the calculator. It calculates the concentration (mg/mL, µg/µL) and the volume per sample (mL, µL).
Storage
BEFORE RECONSTITUTION
Room temperature, protected from direct light, in original packaging. Refrigerator not required.
AFTER RECONSTITUTION
+2 °C to +8 °C, up to 60 days with Peptide Matrix Water. Discard any remainder after this period.
FREEZING
Not recommended. Freeze/thaw cycles degrade peptide structure.
Four mistakes to avoid
1. Shaking "to dissolve faster"
Foam = denaturation. Only gentle rolling between the palms.
2. Inappropriate solvent
For peptide stability use only sterile, specially formulated solvent — recommended Peptide Matrix Water.
3. Ignoring slight turbidity
Not fully clear = the sample does not meet the criteria for use.
4. Taking it out of the refrigerator "for an hour–two"
Short exposures add up and compromise stability.
Research status: All Peptology products are intended for laboratory and research use only. They are not medicinal products, not approved for human or veterinary use and do not substitute medical advice. The described protocol is standard laboratory practice for working with lyophilized peptides.
Shipping information
🚚 Shipping information
-
Products in our warehouse – orders placed by 15:00 on working days are dispatched the same day, later orders on the next working day.
-
Delivery with GLS to your address in 3–5 working days.
-
Shipping costs €5 and is free from €50.
Frequently Asked Questions (FAQ)
What is the target of ACE-031?
ACE-031 is ActRIIB-Fc and sequesters myostatin/activin and related ligands (incl. GDF-11, BMP9/10), reducing signaling through ActRIIB.
Why was development in DMD stopped?
Because of signals for epistaxis/telangiectasias and regulatory discussions; the program was terminated.
Is there a Phase III?
No – there are no published Phase III trials, ACE-031 remains of scientific interest mainly for research purposes.
Where can I buy ACE-031 in Europe and what does it cost?
You can buy ACE-031 in Europe online from Peptology, from 40,00 €. Delivery with GLS in 3–5 working days. Shipping is free from 50,00 €. Payment by card. Purity 99%+, with an HPLC report for every batch.
Laboratory Analysis
ACE-031 - 1mg - Batch - 0226 - Purity
